Multi-disciplinary surgical approach to the management of patients with renal cell carcinoma with venous tumor thrombus: 15 year experience and lessons learned by unknown
RESEARCH ARTICLE Open Access
Multi-disciplinary surgical approach to the
management of patients with renal cell
carcinoma with venous tumor thrombus:
15 year experience and lessons learned
Bishoy A. Gayed1†, Ramy Youssef1†, Oussama Darwish1, Payal Kapur2, Aditya Bagrodia1, James Brugarolas3,
Ganesh Raj1, J. Michael DiMaio4, Arthur Sagalowsky1 and Vitaly Margulis1*
Abstract
Background: The management of patients with renal cell carcinoma (RCC) with venous tumor thrombus (VTT)
is challenging. We report our 15 year experience in the management of patients with RCC with VTT utilizing a
multidisciplinary team approach, highlighting improved total and specifically Clavien III-V complication rates.
Methods: We reviewed the records of 146 consecutive patients who underwent radical nephrectomy with venous
thrombectomy between 1998 and 2012. Data on patient history, staging, surgical techniques, morbidity, and survival
were analyzed. Additionally, complication rates between two surgical eras, 1998–2006 and 2006–2012, were assessed.
Results: The study included 146 patients, 97 males (66 %), and a median age of 61 years (range, 24–83). Overall
complications rate was 53 %, high grade complications (Clavien III -V) occurred in 10 % of patients. Most importantly,
there was a lower incidence of overall and high grade complications (45 % and 8 %, respectively) in the last 6 years
compared to the earlier surgeries included in the study (67 % and 13 % respectively) [p = .008 and .03, respectively).
30 day postoperative mortality was 2.7 %. 5 year overall survival (5Y- OS) and 5 year cancer specific survival (5Y- CSS)
were 51 % and 40 %, respectively. Metastasis was the only independent predictor factor for CSS (HR 3.8, CI 1.9-7.6 and
p < .001) and OS (HR 2.6, CI 1.5-4.7 and p = .001) in all patients.
Conclusions: Our data suggest that patients with RCC and VTT can be treated safely utilizing a multidisciplinary team
approach leading to a decrease in complication rates.
Key words: Renal cell carcinoma, IVC thrombus, Outcomes
Background
In 2015, there will be nearly 62000 newly diagnosed
cases of RCC and 14000 deaths due to RCC [1]. RCC
has the propensity to extend into the renal vein, inferior
vena cava (IVC) and up to the right atrium in up to
23 %, 10 %, and 1 % of cases, respectively [2, 3]. Refine-
ments in clinical imaging, with CT and MRI, have im-
proved accurate evaluation of primary tumors and the
level of venous tumor thrombus (VTT) [2, 4]. Radical
nephrectomy (RN) and IVC thrombectomy (IVCT) is
challenging, particularly with a high VTT level [3–5].
Throughout the course of our experience, we have
continued to improve our technique employing several
modifications. We believe the most important modifica-
tion we have made has been constantly ensuring we have
the same urologic oncologists, cardiac anesthesia team,
cardiac surgeons, and a dedicated cardiac scrub team at
all cases. This brings familiarity to these challenging
cases, which helps better manage both intraoperative
and postoperative complications. Additionally, we have
deferred from preforming sternotomies for high level 3
cases to avoid the morbidity of a sternotomy. With ef-
fective liver mobilization and use of pericardial windows
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extirpation of high level 3 is facilitated both safely and
effectively. This has equated to improved patient recov-
ery in the postoperative setting.
Herein, we review the management of RCC with VTT
in the last 15 years, aiming to outline prognostic factors,
outcomes, and complication rates in the context of a
dedicated multidisciplinary surgical team.
Methods
Patient selection
Clinical data from electronic medical records of patients
treated by radical nephrectomy (RN) for RCC with renal
vein or IVC thrombus at our institution from January
1998 to June 2012 were retrospectively analyzed and
placed into a UT Southwestern Medical Center IRB ap-
proved database. Research was carried out in compliance
with the Helsinki Declaration. We did not obtain in-
formed consent from patients, as this was a retrospective
study. Relevant clinical data, pathological features, surgi-
cal techniques, hospital stay, perioperative morbidity and
mortality, follow up and survival data were collected.
Preoperative evaluation and surgical techniques
The tumors were routinely staged by using abdominal
and chest CT scans and chest radiography. MRI was
used for better evaluation of VTT level at the discretion
of the treating physician. Bone scans were used select-
ively when clinically indicated. Tumor thrombus exten-
sion was classified into 4 levels: level I, extension into
the renal vein; level II, extension into the infrahepatic
IVC; level III, IVC extension to the level of hepatic veins
but below the diaphragm; and level IV, IVC extension
above the diaphragm [6].
Preoperative renal artery angioembolization was per-
formed at the discretion of the surgeon to facilitate ar-
terial vascular control in patients with bulky tumor
thrombus, hilar adenopathy, or hypervascularity. Surger-
ies were managed by a multidisciplinary team which in-
cluded an experienced urologic oncology surgeon,
cardiothoracic surgeon and cardiac anesthesiologist, and
cardiac scrub team. Trans-esophageal echocardiography
was used intraoperatively by the anesthesiologist to ver-
ify the cephalad extent of the thrombus, to monitor for
tumor emboli, to confirm the complete removal of VTT,
and to assess hemodynamic stability. Data regarding the
duration of surgery, estimated blood loss and intraopera-
tive complications were recorded.
Pathologic evaluation
Pathologic staging was assigned according to the 2010
TNM staging system [7]. Grading of the tumors was
evaluated according to Fuhrman classification [8]. Add-
itionally, pathological tumor size, adrenal involvement,
regional lymph node (LN) involvement, tumor necrosis,
histopathological cell type and the presence of sarcoma-
toid differentiation were recorded.
Outcome evaluation and statistical analysis
Perioperative morbidity and mortality within the first 30
and 90 days were recorded and graded according to the
Clavien-Dindo grading system [9]. Patients without me-
tastases were routinely followed after surgery every
3 months in the first year, every 6 months in the second
year and then annually. Follow up included history,
physical examination, metabolic panel, liver function
tests, chest x-ray and an abdominal CT scan. Bone scan,
chest CT, positron emission tomography or MRI were
performed when clinically indicated.
Survival time was calculated from the date of the oper-
ation to the date of last follow up or date of death. Dis-
ease recurrence was defined as local failure in the RN
bed or regional LNs, or distant metastasis. Disease-free
survival (DFS) was defined as the time between the date
of surgery and the development of local recurrence or
distant metastasis. Censored survival values represent
patients who were alive without clinical evidence of dis-
ease at the last follow up. Cancer-specific survival (CSS)
and overall survival (OS) were defined as the time be-
tween the date of surgery and death due to cancer (CSS)
or due to any cause (OS). The following factors that
could potentially affect outcomes were analyzed: age,
gender, body mass index and performance status; T
stage, VTT level, pathological tumor size, nodal involve-
ment, metastasis at presentation, grade, sarcomatoid dif-
ferentiation, histological subtype, fat invasion, adrenal
involvement and tumor necrosis. Endpoints were CSS
and OS. DFS was analyzed only in M0 patients. Finally,
independent predictors of disease recurrence and cancer
specific mortality were determined using multivariate Cox
Regression analyses including only factors significant in
univariate analyses. Statistically significant difference was




Patient demographics and clinical characteristics of the
146 patients included in the study are shown in Table 1.
Hematuria and flank pain were the most common pre-
senting symptoms (46 % and 38 % respectively). Overall,
42 (29 %) presented with distant metastases (M+), 29
patients (20 %) had LN+. and there was no significant
relation between the VTT level and presence of M+ or
LN+ disease (p = 0.3). Metastatic sites included: lungs
(11 patients), liver (5 patients), bone (5 patients), adrenal
(5 patients; 4 in the ipsilateral and 1 in the contralateral
adrenal) and multiple sites (5 patients).
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MRI was performed in 95 (65 %) patients for better
determination of VTT level. Patients with IVC thrombus
had a 26 % incidence of LN+ disease versus 14 % in
those with RV only thrombus (p = .07). The mean num-
ber of removed and positive LNs were 5 (range, 0–33)
and 1 (range, 1–22); respectively. Detailed pathological
features are shown in Table 2.
Surgical intervention
Surgical parameters and postoperative hospital stay data
are included in the Additional file 1: Table S1. Preopera-
tive renal artery angioembolization was performed in
27.4 % of all patients with any venous thrombus, and in
49.3 % of patients with level 2–4 thrombi. Chevron inci-
sion was the most common approach and was per-
formed in all patients with level III and IV VTT (with
midline strenotomy in cases where cardio-pulmonary
bypass was needed). IVC clamping was used in most
cases of level II and III VTT. Suprahepatic control of
the IVC and control of porta hepatis were gained in level
III VTT. More aggressive cardiothoracic procedures
were reserved for patients with level IV and 3 patients
with level III VTT who were hemodynamically unstable
during the initial cross-clamping of the IVC. Right heart
venovenous bypass was used to assist in removal of
VTT in these 3 patients. Cardio-pulmonary bypass was
needed in 5 patients with level IV VTT with mean by-
pass, aortic cross clamping and circulatory arrest times
of 124, 59 and 25 min respectively.
Mean estimated blood loss was 1.5 L and blood loss
was greatest in patients with level IV VTT. The mean
operative time was around 5 h and it was correlated to
level of thrombus (5.5, 6 and 6.5 h in level II, III and IV;
respectively). Mean hospital stay was 8.8 days (range, 1–
63) and mean ICU stay was 3 days (range, 0–51). Three
patients had a complicated postoperative course and re-
quired longer care.
Peri-operative morbidity and mortality
Out of 146 patients, 4 (2.7 %) and 5 (3.4 %) patients died
within 30 and 90 days after surgery, respectively. The
causes of death included: pulmonary embolism, coagulop-
athy, bleeding and pneumonia. Complications occurred in
77 (53 %) of patients and only 15 patients (10 %) had high
grade (Clavien III-V) complications (Tables 3 and 4). The
most common perioperative complication was prolonged
ileus (12 %). The occurrence of complications did not
correlate with VTT level or other clinical parameters in-
cluding patient age, performance status, smoking and pre-
operative renal artery embolization (p > 0.05). However,
correlation was seen with duration of surgery (p = 0.04)
and intraoperative blood loss (p = 0.016). Most import-
antly, there was a lower incidence of overall and high
grade complications (45 % and 8 %, respectively) in the
last 6 years compared to the earlier surgeries included in
the study (67 % and 13 % respectively) (p = .008 and .03,
respectively) (Table 5).
Oncological outcomes
Patients were followed up after RN for a median of
16 months (mean 26, range 0–163 months). At the time
of the analysis, overall mortality was 44 % with a median
Table 1 Patient demographics and clinical characteristics
All (%) Era 1 (%) Era 2 (%)
All patients (%) 146 (100) 64 (44) 82 (56)
Age, median (range) y 61 ± 12 57 ± 12 64 ± 11
(24–82) (35–83) (24–82)
Sex
Male 97 (66) 42 (66) 55 (67)
Female 49 (34) 22 (34) 27 (33)
Side
Right 82 (56) 34 (53) 48 (59)
Left 64 (44) 30 (47) 34 (41)
Race or ethnic group
Caucasian 96 (66) 41 (64) 55 (67)
Hispanic 25 (17) 15 (23) 10 (12)
Black 15 (10) 4 (6) 11 (13)
Other 10 (7) 4 (6) 6 (7)
Presenting symptoms
Asymptomatic 22 (15) 7 (11) 15 (18)
Flank pain 56 (38) 27 (42) 29 (35)
Hematuria 67 (46) 34 (53) 33 (40)
Weight loss 43 (30) 16 (25) 27 (33)
Lower extremity swelling 13 (9) 6 (9) 7 (9)
Change in appetite 13 (9) 4 (6) 9 (11)
Feeling of fullness 9 (6) 4 (6) 5 (6)
Distended subcutaneous veins 2 (1) 0 (0) 2 (2)
DVT/PE 8 (6) 4 (6) 4 (5)
Smoking 51 (35) 14 (22) 37 (45)
BMI median 28 ± 5.6 28 ± 4.9 26 ± 6.0
(range) (17–56) (19–46) (17–56)
Obese (BMI≥ 30) 34 (23) 17 (27) 17 (21)
ECOG
0 27 (18) 17 (27) 10 (12)
1 93 (64) 43 (67) 50 (61)
2 20 (14) 2 (3) 18 (22)
3 6 (4) 2 (3) 4 (5)
ASA
2 51 (35) 24 (38) 27 (33)
3 73 (50) 32 (50) 41 (50)
4 22 (15) 8 (12) 14 (17)
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survival of 47 ± 4 months (range 38–56 months) and
34 % cancer specific mortality with a median CSS of 62
± 17 months (range 29–94 months). Kaplan-Meier Sur-
vival analysis showed CSS at 2,3 and 5 years to be 70 %,
62 % and 51 %; OS at 2, 3 and 5 years to be 64 %, 57 %
and 40 %; respectively (Fig. 1a). There was no significant
difference in survival comparing the last 6 years to an
earlier period with 3Y- CSS 62 % in both eras.
Prognostic factors
Kaplan-Meier survival analysis (Fig. 1b) demonstrated a
significant difference between CSS rates in M0 and M+
patients (5Y-CSS was 68 % and 17 % in M0 and M+ pa-
tients; respectively, p < 0.001). Median CSS was 11 ±
4 months for M+ patients, while it was not yet reached
for M0 patients. Multivariate Cox regression analyses
(data not shown) demonstrated that M+ was the only
Table 2 Pathological Features of Entire Cohort
Characteristic Total (%) Level I (%) Level II (%) Level III (%) Level IV (%) P value
146 (100) 77 (53) 48 (33) 12 (8) 9 (6)
T stage <0.001
T3a 75 (51) 75 (97) 0 0 0
T3b 51 (35) 0 40 (83) 11 (92) 0
T3c 8 (6) 0 0 0 8 (89)
T4 12 (8) 2 (3) 8 (17) 1 (8) 1 (11)
Grade 0.015
1 1 (1) 0 0 1 (8) 0
2 24 (16) 17 (22) 5 (10) 1 (8) 1 (11)
3 86 (59) 39 (51) 32 (67) 10 (84) 5 (56)
4 35 (24) 21 (27) 1 (23) 0 3 (33)
Path tumor size (cm) 10.2 ± 4.5 9.2 ± 4.3 11.7 ± 4.6 10 ± 2.9 12 ± 6.3 0.02
(2–25) (2–23) (3.5-25) (5.5-15) (5–22)
Metastasis 0.3
Absent 104 (71) 56 (73) 31 (65) 11 (92) 6 (67)
Present 42 (29) 21 (27) 17 (35) 1 (8) 3 (33)
LN 0.01
N0 69 (47) 30 (39) 29 (60) 5 (42) 5 (56)
Nx 48 (33) 36 (47) 6 (13) 4 (33) 2 (22)
N+ 29 (20) 11 (14) 13 (27) 3 (25) 2 (22)
Sarcomatoid Differentiation 0.3
Absent 127 (87) 68 (88) 39 (81) 12 (100) 8 (89)
Present 19 (13) 9 (1) 9 (19) 0 1 (11)
Adrenal Involvement 0.08
Absent 128 (88) 72 (94) 38 (79) 11 (92) 7 (78)
Present 18 (12) 5 (6) 10 (21) 1 (8) 2 (22)
Tumor Necrosis 0.4
Absent 52 (36) 32 (42) 15 (31) 3 (25) 2 (22)
Present 94 (64) 45 (58) 33 (69) 9 (75) 7 (78)
Fat Invasion 0.3
Absent 28 (19) 18 (23) 7 (15) 3 (25) 0 (0)
Present 118 (81) 59 (77) 41 (85) 9 (75) 9 (100)
Histological Subtype 0.7
Non clear cell 11 (8) 5 (6) 5 (10) 1 (8) 0 (0)
Clear cell 135 (92) 72 (94) 43 (90) 11 (92) 9 (100)
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independent predictor factor for CSS (HR 3.8, CI 1.9-7.6
and p < .001) and OS (HR 2.6, CI 1.5-4.7 and p = .001).
LN+ was associated with a trend toward a poor CSS
(HR 1.9, CI .97-3.6 and p = .06). In M+ patients, LN+
was the only factor significantly associated with poor
oncological outcomes as shown from CSS analysis (HR
2.3, CI 1–5 and P = .03), and in OS analysis (HR 2, CI
.96 – 4.3 and P = .06). In M0 patients, high VTT level
(III and IV compared to I and II) was among the inde-
pendent predictors of disease recurrence (HR 4.4, CI
2.1-9.4 and P < .001) and cancer specific mortality (HR
6.5, CI 2–21.2; p = .002) in multivariate Cox regression
analysis. Other independent predictors of poor onco-
logical outcomes included larger tumor size (>13 cm)
and sarcomatoid differentiation (data not shown).
Discussion
Aggressive surgical resection is indicated in RCC with
VTT as nephrectomy alone is associated with dismal
prognosis [10]. Through an experienced team, consisting
of a urologic oncology surgeon, cardiothoracic surgeon,
cardiac anesthesiologist, and cardiac scrub team we were
able to achieve satisfactory surgical and oncological out-
comes and decrease the incidence of complications.
We noticed a significant reduction in the rate of overall
and high grade complications (45 % and 8 %, respectively)
in the last 6 years compared to the earlier surgeries in-
cluded in the study (67 % and 13 % respectively) [p = .008
and .03, respectively]. We believe this reduction may be
due to our multidisciplinary team approach, which pro-
vides uniform and consistent management of patients
with VTT. The team approach further supports meticu-
lous perioperative and postoperative planning and de-
livery of care, refinement of surgical technique, and
improved anesthesia.
In terms of oncological outcomes, metastasis was
found to be the strongest independent predictor of sur-
vival. Patients with M+ had a 3.8 times risk of cancer
specific mortality compared to M0 patients (p < .001).
While M0 patients had 5-Y CSS of 68 % and median
survival that was not reached yet, M+ patients had a 17 %
5-Y CSS and 11 months median survival. Our survival rates
were superior to those reported in the literature for M0
patients [3–5, 11–24] but they were similarly poor in M+
patients who were reported to have 4-30 % 5Y-CSS and
11–20 months median survival [3–5, 11–18, 21]. In this
study, 29 % of patients had metastasis at presentation. This
incidence was even higher in other series [14, 16]. Surgery
might be indicated not only to improve oncological
Table 3 Overall complications and grading according to Clavien-Dindo system
Total (%) Level I (%) Level II (%) Level III (%) Level IV (%) P value
146 (100) 77 (52.7) 48 (32.9) 12 (8.2) 9 (6.2)
Overall Complications 77 (53) 38 (49) 27 (56) 7 (58) 5 (56) .86
Ileus/bowel 18 (12) 10 (13) 4 (8) 4 (33) 0 (0) .07
DVT 5 (3) 1 (1) 1 (2) 2 (17) 1 (11) .03
Pleural effusion 8 (6) 3 (4) 5 (10) 0 0 (0) .4
Acute renal failure 7 (5) 4 (5) 2 (4) 0 1 (11) .7
Coagulopathy 5 (3) 1 (1) 3 (6) 0 1 (11) .2
PE 10 (7) 2 (3) 1 (2) 4 (33) 3 (33) .001
Pneumonia 2 (1) 1 (1) 1 (2) 0 0 (0) .9
Perioperative mortality 11 (8) 3 (4) 7(15) 0 1 (11) 0.1
Clavien I-II 63 (43) 33 (43) 21 (44) 7 (58) 2 (22) .02
Clavien III-V 15 (10) 5 (6) 6 (13) 0 4 (44)
Table 4 Overall complications and grading according to
Clavien-Dindo system by Era
Total (%) Era I (%) Era II (%) P value
146 (100) 64 (44) 82 (56)
Overall Complications 77 (53) 43 (67) 34 (42) .002
Ileus/bowel 18 (12) 10 (16) 8 (10) .3
DVT 5 (3) 2 (3) 3 (4) .9
Pleural effusion 8 (6) 3 (5) 5 (6) .7
Acute renal failure 7 (5) 4 (6) 3 (4) .5
Coagulopathy 5 (3) 5 (8) 0 (0) .01
PE 10 (7) 1 (2) 9 (11) .025
Pneumonia 2 (1) 1 (2) 1 (1) .9
Perioperative mortality 11 (8) 2 (3) 9 (11) 0.08
Clavien I-II 63 (43) 35 (55) 28 (34) .02
Clavien III-V 15(10) 8 (13) 7 (8)
Table 5 Overall High Grade Complication Rate by ERA
Surgery Era 1998-2006 2006-2012 p value
Overall Complication Rate 67 % 45 % .008
High Grade Complications
Clavien III - V
13 % 8 % .030
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outcomes but also to relieve symptoms and provide better
quality of life. However, performance status and associated
comorbidities should be considered [10].
Overall, LN+ showed a trend toward poor CSS (HR
1.9, CI and p = .06) and achieved prognostic significance
only in M+ patients (HR 2.3 and p = .03). Perhaps, statis-
tical significance, in the analysis involving all patients,
would be reached if the sample size was larger and/or
follow up was longer. The independent prognostic role
of LN+ was reported in other RN and IVCT series [12,
14, 21, 24]. Previous studies support the role of aggres-
sive debulking of regional nodal disease at the time of
cytoreductive RN for metastatic RCC [2, 25, 26].
There has been wide variation in reporting different prog-
nostic factors and the prognostic value of VTT level has
been debated. Our prognostic factors were similar to those
reported in the largest European study that included 1192
patients from 13 European centers [12] and the US based
analysis including 1875 patients with RCC and VTT from
the SEER database [27]. In both studies, metastasis was the
most important independent predictor of worse survival.
Interestingly, analysis of data for all patients showed
that metastasis was the only independent predictor of
oncological outcomes. However, in M0 patients, features
associated with aggressive tumor behavior (high level
VTT, large tumor size, and sarcomatoid differentiation)
had an independent prognostic role. The size of the
tumor has been implicated in staging of RCC. Large
tumor size was among the strongest predictors of worse
survival in the international RCC-VTT consortium that
included 1215 RN and IVCT from 11 American and
European institutions [21] as well as in a population
based analysis including 1875 patients with RCC and
VTT from the SEER database [27]. Sarcomatoid differen-
tiation was reported with an incidence of 9 % and was
among the independent predictors of worse survival in
RN and IVCT series [3, 14, 20]. We found sarcomatoid
differentiation in 13 % of tumors and it did not correlate
with higher VTT levels, as 95 % of tumors with sarco-
matoid differentiation had level I or II VTT.
We acknowledge several limitations in this review.
First, is the retrospective design with its inherited bias.
Fig. 1 a) Kaplan-Meier estimates of cancer-specific survival and overall survival for 146 patients after radical nephrectomy and venous thrombectomy.
b) Kaplan-Meier estimates of cancer-specific survival stratified by presence of metastasis at presentation and LN status for 146 patients after radical
nephrectomy and venous thrombectomy
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Second, while our multidisciplinary approach has lead to
a decrease in the rate of complications, other factors
may have also lead to improved outcomes. Improvement
in surgical technique, enhanced understanding of the
biology of the disease, and improved delivery of medical
care throughout the course of the study may have also
lead to improved patient outcomes. Lastly, the impact of
venous wall invasion by thrombus could not be evalu-
ated, as it was not reported by consistent pathologic cri-
teria over the period under review.
Conclusions
RN and VTT is a challenging surgery and while, im-
provements in surgical techniques and perioperative care
have decreased surgical morbidity and mortality, we
strongly advocate for management of these patients with
an experienced multidisciplinary team. Our approach
has resulted in improved overall complications and most
importantly, high grade complications. A strong working
relationship between all team members helps develop
meticulous perioperative and postoperative planning and
delivery of care, refinement of surgical technique, and
improved anesthesia.
Additional file
Additional file 1: Table S1. Surgical Parameters and postoperative
hospital stay. (DOCX 101 kb)
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